Search Results 2361-2370 of 20192 for Receptor

  1. Publications - Jiasen Ma, Ph.D. - Mayo Clinic

    Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nat Chem Biol. 2020 Mar; 16 (3):267-277 Epub 2020 Jan 20. View PubMed; Ahn ...

  2. Innovative CAR-TIL immunotherapy against melanoma - Mayo Clinic

    The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B cell ...

  3. Study Of Carboplatin And Mirvetuximab Soravtansine In First-Line Treatment Of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube Or Primary Peritoneal Cancer - Mayo Clinic

    Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor ...

  4. Publications - Mehrdad Hefazi Torghabeh, M.D. - Mayo Clinic

    AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells. Cancer Immunol Res. 2023 Sep 01; 11(9):1222-1236. View PubMed; Sakemura ...

  5. Neurosurgery - Clinical trials

    Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...

  6. Neurosurgery - Clinical trials

    Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...

  7. Neurology - Clinical trials - Mayo Clinic

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  8. Neurology - Clinical trials - Mayo Clinic

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  9. A Study of the Safety and Effectiveness of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration - Mayo Clinic

    Treatment with systemic anti-VEGF medication (e.g., bevacizumab, ziv-aflibercept) or VEGF-receptor inhibitor (e.g., sunitinib, sorafenib, pazopanib) within ...

  10. Study of Pembrolizumab With Ipilimumab or Placebo in Participants with Untreated Metastatic Non-small Cell Lung Cancer - Mayo Clinic

    Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor ( ...